LC
Lineage Cell Therapeutics, Inc.
LCTX · AMEX
$1.07 +0.00% (+$0.00)
1M +0.94%
Market Cap $266.7M
P/E Ratio -
Div. Yield -
ROE 71.14%
Piotroski F-Score Weak
3/9Valuation
23 /100
Expensive P/B 4.38x
P/S 20.39x
EV/FFO N/A
Growth
14 /100
Declining Book val. growth 15.31%
Rev. growth 0.33%
FCF growth N/A
Profitability
20 /100
Weak Op. margin 205.23%
Gross margin 96.59%
FCF margin 182.98%
Quality
2 /100
Poor ROA 30.37%
ROIC 23.25%
Asset turnover 0.12x
Debt
100 /100
Low Current ratio 6.61x
Debt/Equity 0.04x
Debt/Assets N/A
Stability
8 /100
Unstable EPS volatility 128.37%
Beta 1.55x
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o LCTX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Brian Culley
Employees
75
Headquarters
Carlsbad
Prihajajoči dogodki
05 NOV.
Earnings
Upcoming earnings report